GKSL Acquires Parekhs Hospital Pvt. Ltd. for ₹77 Crore to Expand Healthcare Presence
Gujarat Kidney And Superspeciality Limited acquired Parekhs Hospital Private Limited for ₹77 crore. This acquisition aims to strengthen GKSL's healthcare sector presence and diversify its business. Parekhs Hospital reported a turnover of ₹25.67 crore in FY25.
The acquisition of a hospital is a significant corporate action that will likely impact the company's market presence and future growth, justifying a medium impact.
The acquisition of another entity is a positive step for the company's expansion and diversification strategy in the healthcare sector.
Gujarat Kidney And Superspeciality Limited (GKSL) has announced the execution of an agreement to acquire Parekhs Hospital Private Limited, a wholly-owned subsidiary, on March 22, 2026. This strategic acquisition is aimed at strengthening GKSL's presence in the healthcare sector and diversifying its business portfolio.
Parekhs Hospital Private Limited, incorporated in Ahmedabad, Gujarat, has an authorized share capital of ₹85,00,000 and a paid-up capital of ₹25,50,000, comprising 255,000 equity shares of ₹10 each. The acquisition involves 100% of the equity shares.
The transaction is a cash consideration with an acquisition cost of ₹77,00,00,000 (seventy-seven crore rupees only). Parekhs Hospital Private Limited operates in the medical and healthcare service provider industry. Its consolidated turnover for the last three financial years was ₹25,66,69,000 for FY 2024-25, ₹26,35,59,000 for FY 2023-24, and ₹24,06,44,000 for FY 2022-23. No governmental or regulatory approvals are required for this acquisition, and it does not fall within related party transactions.
What to do with a filing like this
Gujarat Kidney And Super Speciality Limited filed this with the NSE as a statutory disclosure, categorised under acquisition. It is a primary document, not a recommendation, and the desk marks it medium impact: worth reading, rarely worth acting on by itself.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by Gujarat Kidney And Super Speciality Limited. Read the original for the full detail.